Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
147
datasets available to search
ShareScore release 0.9.0
Dataset results
147 results for “Disease mapping”
Data from: Mapping and validation of a major QTL affecting resistance to pancreas disease (salmonid alphavirus) in Atlantic salmon (Salmo salar)
Pancreas disease (PD), caused by a salmonid alphavirus (SAV), has a large negative economic and animal welfare impact on Atlantic salmon aquaculture. Evidence for genetic variation in host resistance to this disease has been reported, suggesting that selective breeding may potentially form an important component of disease control. The aim of this study was to explore the genetic architecture of resistance to PD, using survival data collected from two unrelated populations of Atlantic salmon; one challenged with SAV as fry in freshwater (POP 1) and one challenged with SAV as post-smolts in sea water (POP 2). Analyses of the binary survival data revealed a moderate-to-high heritability for host resistance to PD in both populations (fry POP 1 h2~0.5; post-smolt POP 2 h2~0.4). Subsets of both populations were genotyped for single nucleotide polymorphism markers, and six putative resistance quantitative trait loci (QTL) were identified. One of these QTL was mapped to the same location on chromosome 3 in both populations, reaching chromosome-wide significance in both the sire- and dam-based analyses in POP 1, and genome-wide significance in a combined analysis in POP 2. This independently verified QTL explains a significant proportion of host genetic variation in resistance to PD in both populations, suggesting a common underlying mechanism for genetic resistance across lifecycle stages. Markers associated with this QTL are being incorporated into selective breeding programs to improve PD resistance.
Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: can disease-specific utilities be obtained?
<p class="Default"><b>Introduction</b></p> <p class="Default">Innovations in head and neck cancer (HNC) treatment are often subject to economic evaluation prior to their reimbursement and subsequent access for patients. Mapping functions facilitate economic evaluation of new treatments when the required utility data is absent, but quality of life data is available. The objective of this study is to develop a mapping function translating the EORTC QLQ-C30 to EQ-5D-derived utilities for HNC through regression modeling, and to explore the added value of disease-specific EORTC QLQ-H&N35 scales to the model.</p> <p class="Default"> </p> <p class="Default"><b>Methods</b></p> <p class="Default">Data was obtained on patients with primary HNC treated with curative intent derived from two hospitals. Model development was conducted in two phases: 1. Predictor selection based on theory- and data-driven methods, resulting in three sets of potential predictors from the quality of life questionnaires; 2. Selection of the best out of four methods: ordinary-least squares, mixed-effects linear, Cox and beta regression, using the first set of predictors from EORTC QLQ-C30 scales with most correspondence to EQ-5D dimensions. Using a stepwise approach, we assessed added values of predictors in the other two sets. Model fit was assessed using Akaike and Bayesian Information Criterion (AIC and BIC) and model performance was evaluated by MAE, RMSE and limits of agreement (LOA).</p> <p class="Default"> </p> <p class="Default"><b>Results </b></p> <p class="Default">The beta regression model showed best model fit, with global health status, physical-, role- and emotional functioning and pain scales as predictors. Adding HNC-specific scales did not improve the model. Model performance was reasonable; R<sup>2</sup>=0.39, MAE=0.0949, RMSE=0.1209, 95% LOA of -0.243 to 0.231 (bias -0.01), with an error correlation of 0.32. The estimated shrinkage factor was 0.90.</p> <p class="Default"> </p> <p class="Default"><b>Conclusions</b></p> <p>Selected scales from the EORTC QLQ-C30 can be used to estimate utilities for HNC using beta regression. Including EORTC QLQ-H&N35 scales does not improve the mapping function. The mapping model may serve as a tool to enable cost-effectiveness analyses of innovative HNC treatments, for example for reimbursement issues. Further research should assess the robustness and generalizability of the function by validating the model in an external cohort of HNC patients.</p>
Data from: Integrating regulatory surveys and citizen science to map outbreaks of forest diseases: acute oak decline in England and Wales
The number of emerging tree diseases has increased rapidly in recent times, with severe environmental and economic consequences. Systematic regulatory surveys to detect and establish the distribution of pests are crucial for successful management efforts, but resource intensive and costly. Volunteers who identify potential invasive species can form an important early warning network in tree health, however, what these data can tell us and how they can be best used to inform and direct official survey effort is not clear. Here we use an extensive dataset on Acute Oak Decline (AOD) as an opportunity to ask how verified data received from the public can be utilised. Information on the distribution of AOD was available as (i) systematic regulatory surveys conducted throughout England and Wales (ii) ad-hoc sightings reported by land owners, land managers and members of the public (i.e. 'self-reported' cases). By using the available self-reported cases at the design stage the systematic survey could focus on defining the boundaries of the affected area. This maximised the use of available resources and highlights the benefits to be gained by developing strategies to enhance volunteer efforts in future programs.
Genetic mapping of serum metabolome to chronic diseases among Han Chinese
Open the record for dataset details and reuse information.
Molecular mapping of urinary complement peptides in kidney diseases
<p><strong>Abstract: </strong>Defective complement activation has been associated with various types of kidney disease. This led to the hypothesis that specific urine complement fragments may be associated with kidney disease etiologies, and disease progression may be reflected by changes in these complement fragments. We investigated the occurrence of complement fragments in urine, their association with kidney function and disease etiology in 16,027 subjects, using mass spectrometry based peptidomics data from the Human Urinary Proteome/Peptidome Database. Twenty-three different urinary peptides originating from complement proteins C3, C4 and factor B (CFB) could be identified. Most C3-derived peptides showed inverse association with estimated glomerular filtration rate (eGFR), while the majority of peptides derived from CFB demonstrated positive association with eGFR. Several peptides derived from the complement proteins C3, C4 and CFB were found significantly associated with specific kidney disease etiologies. These peptides may depict disease-specific complement activation and could serve as non-invasive biomarkers to support development of complement interventions through assessing complement activity for patients’ stratification and monitoring of drug impact. Further investigation of these complement peptides may provide additional insight into disease pathophysiology and could possibly guide therapeutic decisions, especially when targeting complement factors.</p>
Mapping of the dataset of the German National Regsitry for Rare Diseases (NARSE) to Observational Medical Outcomes Partnership Common Data Model (OMOP CDM)
<p>Mapping between the data set of the German National Registry for Rare Diseases ("Nationales Register für Seltene Erkrankungen"; <a href="https://www.narse.de/">NARSE</a>) to Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) using international standards.</p>
Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid
ClinicalTrials.gov study NCT00832429. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Iodine Subtraction Mapping in the Diagnosis of Chronic Pulmonary Thromboembolic Disease
ClinicalTrials.gov study NCT03806907. IPD Sharing: NO. Countries: 0. Publications: 6.
Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls
ClinicalTrials.gov study NCT03675282. IPD Sharing: NO. Countries: 1. Publications: 0.
Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease
ClinicalTrials.gov study NCT03009396. IPD Sharing: NO. Countries: 7. Publications: 0.
Data from: Integrating regulatory surveys and citizen science to map outbreaks of forest diseases: acute oak decline in England and Wales
Open the record for dataset details and reuse information.
Data from: Mapping and validation of a major QTL affecting resistance to pancreas disease (salmonid alphavirus) in Atlantic salmon (Salmo salar)
Open the record for dataset details and reuse information.
Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: can disease-specific utilities be obtained?
Open the record for dataset details and reuse information.
Comprehensive mapping of genetic variation at Epromoters reveals pleiotropic association with multiple disease traits
GEO Series GSE268615. Homo sapiens. 12 samples. Type: Other.
Allelic expression mapping across cell lineages reveal repressor disruption among disease SNPs
GEO Series GSE53837. Homo sapiens. 41 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
An integrated organoid omics map extends modeling potential of kidney disease
GEO Series GSE213972. Homo sapiens. 16 samples. Type: Expression profiling by high throughput sequencing.
RNA-Seq based transcriptional map of bovine respiratory disease pathogen 'Histophilus somni 2336'
GEO Series GSE29578. Histophilus somni. 1 samples. Type: Expression profiling by high throughput sequencing.
Genome-wide maps of enhancer regulation connect risk variants to disease genes
GEO Series GSE285157. Homo sapiens. 16 samples. Type: Expression profiling by high throughput sequencing.
RNA-sequencing for dynamic epi-transcriptomic landscape mapping with disease progression in ER-positive breast cancer
GEO Series GSE176534. Homo sapiens. 9 samples. Type: Expression profiling by high throughput sequencing.
Quantitative trait loci mapped for TCF21 binding, chromatin accessibility and chromosomal looping in coronary artery smooth muscle cells reveal molecular mechanisms of coronary disease loci (ChIP-Seq)
GEO Series GSE141751. Homo sapiens. 1 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.